Wednesday, December 04, 2019 9:07:25 AM
No evidence of cardiotoxicity to date; 40% of 10 patients dosed at 120 mg/m2 demonstrate efficacy; trial progresses in Europe to 210 mg/m2
HOUSTON, TX - December 4, 2019 — Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced additional positive interim safety and efficacy data from one of the Company’s two ongoing open label, single arm Phase 1/2 studies of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia ("AML").
The Phase 1 portion of these clinical trials, which are described in more detail later in this press release, is designed to establish the safety of Annamycin and to determine the Recommended Phase 2 Dose to be used in the Phase 2 portion of the trials. While the Primary Endpoint of the Phase 1 portion is safety, a Secondary Endpoint is the assessment of efficacy generally defined as an improvement in bone marrow biopsy results sufficient to qualify patients for a potentially curative bone marrow transplant. The Company cautions not to place undue reliance on interim results.
The third cohort in Poland receiving a single dose of 180 mg/m2 in the Phase 1 dose escalation portion of the trial was completed with no adverse events and the trial will continue to the next cohort of 210 mg/m2. In the US trial, one patient has completed treatment in the second cohort at 120 mg/m2. This brings the total number of patients treated and evaluated at or above 120 mg/m2 to 10. An additional patient in the US has begun treatment at 120 mg/m2 but has yet to complete post-treatment evaluation. The interim results for these 10 patients are 1 CRi (defined as a complete response with incomplete recovery of white blood cells and/or platelets) and 2 partial responses ("PRs" or where bone marrow blasts are reduced 50% and to below 25%). One additional patient was bridged to bone marrow transplant ("BT") based on a sufficient reduction in bone marrow blasts, bringing the total to 4 out of 10 patients at or above 120 mg/m2 who have demonstrated efficacy.
In the latest cohort in Poland, 1 of the 3 patients treated at 180 mg/m2 had a PR sufficient to qualify for a potentially curative bone marrow transplant. The results for all 3 patients were reviewed by the Safety Review Committee, which determined that no drug-related adverse events were observed that would prevent advancing the trial to the next higher dose level of 210 mg/m2. To date in the European trial, only one adverse event related to Annamycin has been reported; a patient experienced grade 2 mucositis (which resolved to grade 1 within 2 days). In the Company’s parallel US clinical trial, one new patient (the first of cohort #2) achieved a "morphologically leukemia free state" or MLFS, which also constitutes a CRi, after receiving a single dose of 120 mg/m2.
If someone tries to convince you to buy a stock they usually have a personal agenda to do so. Not because they are concerned about you making money but about convincing you to buy so they can make money. Same is true for those yelling sell.
Recent MBRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 12:00:16 PM
- Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma • PR Newswire (US) • 09/23/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:31:07 PM
- Moleculin Participates in Virtual Investor "What this Means" Segment • PR Newswire (US) • 09/16/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:15:29 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/13/2024 08:15:24 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/13/2024 08:04:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 12:15:12 PM
- Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma • PR Newswire (US) • 09/09/2024 12:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/03/2024 09:15:55 PM
- Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/03/2024 01:15:00 PM
- Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar • PR Newswire (US) • 08/26/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:10:01 PM
- Moleculin Announces Closing of up to $16.5 Million Public Offering • PR Newswire (US) • 08/19/2024 08:05:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/19/2024 02:06:59 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 08/16/2024 08:54:18 PM
- Moleculin Announces Pricing of up to $16.5 Million Public Offering • PR Newswire (US) • 08/16/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/16/2024 04:15:15 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/15/2024 03:21:01 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/15/2024 01:57:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:05:24 PM
- Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/14/2024 12:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 01:10:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 01:05:10 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM